Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IKS-03 by Iksuda Therapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
IKS-03 is under clinical development by Iksuda Therapeutics and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...
IKS-03 by Iksuda Therapeutics for Follicular Lymphoma: Likelihood of Approval
IKS-03 is under clinical development by Iksuda Therapeutics and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...
IKS-03 by Iksuda Therapeutics for Mantle Cell Lymphoma: Likelihood of Approval
IKS-03 is under clinical development by Iksuda Therapeutics and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...
IKS-03 by Iksuda Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
IKS-03 is under clinical development by Iksuda Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...